EPO Patents = 2

Trademarks = 1

Forward Citations = 17

Loading Chart...

6 inventors (with patents filed for the assignee):

Frank Luyten (5 out of 11 patents)

Francesco Dell'Accio (5 out of 6 patents)

Cosimo De Bari (5 out of 6 patents)

4. Olga De La Rosa (1 out of 6 patents)

5. Wilfried Dalemans (1 out of 4 patents)

6. Eleuterio Lombardo (1 out of 5 patents)

6 patents: Sort by Forward Citations

1. 10660920 - Lymphocyte biomarkers for determining the clinical response to cell therapy (2020-05-26),

2. 9089598 - Method of treating connective tissue defect using chondrocytes selected for phenotypic stability (2015-07-28),

3. 7863045 - Isolation of skeletal precursor cells (2011-01-04),

4. 7842502 - Use of CXCL6 chemokine for inducing precursor cells into chondrocytes (2010-11-30),

5. 7485310 - Use of CXCL6 chemokine in the prevention or repair of cartilage defects (2009-02-03),

6. 7482114 - In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation (2009-01-27),

Tigenix Nv is a biopharmaceutical company that focuses on developing new therapies for damaged or degenerating tissues. Their flagship product, Alofisel, is the first allogeneic stem cell therapy approved for treating complex perianal fistulas in Crohn’s disease patients. Tigenix is dedicated to advancing regenerative medicine and improving the lives of patients with high unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

6 Patents

#6 in Zaventem

#379 in Belgium

Zaventem, Belgium

Tigenix Nv